Volume : 12, Issue : 06, June – 2025

Title:

METABOLIC MULTI-TARGETING THERAPIES: A REVIEW OF DUAL-AGONIST DRUGS AND THEIR IMPACT ON DIABETES, OBESITY, AND ORGAN PROTECTION

Authors :

Nukala Mounika Sivani, Matsa Ganga Bhavani, Karri Naga Pravallika, Bollarapu Syam Deven Babu, Pemmada Sowmya, Mekala Poojitha, Agarapu Lahari, Sagi Anil Kumar

Abstract :

Diseases related to disorders of metabolism such as T2DM and obesity pose significant growing health threats in every region of the globe, frequently complicated by cardiac function impairment, renal failure, and hepatic dysfunction. Drug combinations targeted at a single pathway are known to be of limited efficacy with respect to enduring tolerability. From this perspective, in recent years, dual-agonist therapies have been heralded as a promising multi-target approach in the simultaneous activation of GLP-1, GIP, and glucagon receptors to bring about glycemic control, weight loss, and organ protection. Such drugs as tirzepatide (a GLP-1/GIP dual agonist) and cotadutide (a GLP-1/glucagon dual agonist) have been clinically proven to outperform conventional treatment regimens that improve insulin sensitivity, reduce body weight, and exert cardiovascular and hepatic protective effects. This review explores the mechanisms, impact on other systems, safety profiles, and future prospects of these agents, emphasizing their potential to transform the current landscape of metabolic disease management.. Despite promising results, long-term safety, cost, and accessibility remain critical considerations for widespread adoption.
Keywords:
Dual agonists, GLP-1, GIP, glucagon, tirzepatide, metabolic syndrome, diabetes, obesity, organ protection, multi-target therapy.

Cite This Article:

Please cite this article in press Nukala Mounika Sivani et al., Metabolic Multi-Targeting Therapies: A Review Of Dual-Agonist Drugs And Their Impact On Diabetes, Obesity, And Organ Protection., Indo Am. J. P. Sci, 2025; 12(07).

Number of Downloads : 10

References:

1. Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, Ouatu A, Floria M. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020 Jul 31;2020:3920196.
2. Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol. 2021 Mar 12;11:554961.
3. Guerra, João Victor & Dias, Marieli & Brilhante, Anna & Ferreira Terra, Maiara & García-Arévalo, Marta & Figueira, Ana. (2021). Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases. Nutrients. 13. 2830.
4. Theodorakis N, Nikolaou M. Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1RAs. Biomedicines. 2025; 13(1):135.
5. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, Ostolaza H, Martín C. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020 Aug 30;21(17):6275.
6. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391.
7. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des. 2014;20(31):4944-52.
8. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021 Nov 24;20(1):225
9. Anastasiou IΑ, Argyrakopoulou G, Dalamaga M, Kokkinos A. Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data. Curr Obes Rep. 2025 Apr 11;14(1):34.
10. Rizvi AA, Rizzo M. The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes Metab Syndr Obes. 2022 Apr 5;15:1023-1030.
11. Shroff T, Aina K, Maass C, Cipriano M, Lambrecht J, Tacke F, Mosig A, Loskill P. Studying metabolism with multi-organ chips: new tools for disease modelling, pharmacokinetics and pharmacodynamics. Open Biol. 2022 Mar;12(3):210333
12. Corpeleijn E, Saris WH, Blaak EE. Metabolic flexibility in the development of insulin resistance and type 2 diabetes: effects of lifestyle. Obes Rev. 2009 Mar;10(2):178-93.
13. Zargar AH, Bhansali A, Majumdar A, Maheshwari A, Bhattacharyya A, Dasgupta A, Saboo BD, Sethi BK, Sanyal D, Seshadri KG, Deshpande NR, Kapoor N, Lakhani OJ, Talwalkar PG, Kalra P, Mehrotra RN, Sahay RK, Shukla R, Kant S, Das S, Agarwal SC, Phatak SR, G S, Joshi SR, Shaikh SS, Aravind SR, Goswami S, Ghosh S, Panikar VK, Mohan V. Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists’ perspective. Diabetes Obes Metab. 2025 Jun;27 Suppl 4(Suppl 4):3-20
14. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010 Apr 22;1(1-2):8-23.
15. Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017 Oct;60(10):1851-1861.
16. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024 Jul 24;15:1431292.
17. Knerr PJ, Mowery SA, Douros JD, Premdjee B, Hjøllund KR, He Y, Kruse Hansen AM, Olsen AK, Perez-Tilve D, DiMarchi RD, Finan B. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Mol Metab. 2022 Sep;63:101533.
18. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169.
19. Lee S, Lee DY. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017 Mar;22(1):15-26
20. Barrera JG, Sandoval DA, D’Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol. 2011 Jun 7;7(9):507-16
21. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021 May 11;17(8):2050-2068.
22. Dharmalingam M, Yamasandhi PG. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. Indian J Endocrinol Metab. 2018 May-Jun;22(3):421-428.
23. Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 Receptor Agonists and Kidney Protection. Medicina (Kaunas). 2019 May 31;55(6):233.
24. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013 Jan;3(1):1-58.
25. Qin W, Yang J, Ni Y, Deng C, Ruan Q, Ruan J, Zhou P, Duan K. Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. 2024 Oct;86(1):70-84
26. Darbalaei S, Yuliantie E, Dai A, Chang R, Zhao P, Yang D, Wang MW, Sexton PM, Wootten D. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors. Biochem Pharmacol. 2020 Oct;180:114150.
27. Schneck K, Urva S. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT Pharmacometrics Syst Pharmacol. 2024 Mar;13(3):494-503
28. Calvarysky B, Dotan I, Shepshelovich D, Leader A, Cohen TD. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Saf. 2024 May;47(5):439-451
29. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022 Sep 1;21(1):169.
30. Wilbon SS, Kolonin MG. GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes. Cells. 2024; 13(1):65.